CLC - Charcot-Leyden crystal galectin Gene

Also Known as GAL10; Gal-10; LGALS10; LGALS10A; LPPL_HUMAN

Species: Homo sapiens

Gene Type: protein coding
Gene ID: 1178

About CLC

Cytogenetic location: 19q13.2 Genomic coordinates (GRCh38): 19:39,731,255-39,738,029 (from NCBI)

This gene has 1 transcript (splice variant), 330 orthologues and 16 paralogues. Biased expression in bone marrow (RPKM 112.7), urinary bladder (RPKM 16.5) and 5 other tissues.

Summary

Lysophospholipases are Enzymes that act on biological membranes to regulate the multifunctional lysophospholipids. The protein encoded by this gene is a lysophospholipase expressed in eosinophils and basophils. It hydrolyzes lysophosphatidylcholine to glycerophosphocholine and a free fatty acid. This protein may possess carbohydrate or IgE-binding activities. It is both structurally and functionally related to the Galectin family of beta-galactoside binding proteins. It may be associated with inflammation and some myeloid leukemias. [provided by RefSeq, Jul 2008]

CLC Products (1)

mRNA Protein Name
NM_001828.6 NP_001819.2 galectin-10

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables cysteine-type endopeptidase activity involved in apoptotic process IDA
IDA: Inferred from direct assay
17502455 GOA
enables identical protein binding IPI
IPI: Inferred from physical interaction
25416956 GOA
NOT contributes to lysophospholipase activity IDA
IDA: Inferred from direct assay
11834744 GOA
enables protein binding IPI
IPI: Inferred from physical interaction
11834744 GOA
Biological Process GO Annotation Evidence References Source
involved in T cell apoptotic process IDA
IDA: Inferred from direct assay
17502455 GOA
involved in regulation of T cell anergy IMP
IMP: Inferred from mutant phenotype
17502455 GOA
involved in regulation of T cell cytokine production IMP
IMP: Inferred from mutant phenotype
17502455 GOA
involved in regulation of activated T cell proliferation IMP
IMP: Inferred from mutant phenotype
17502455 GOA
Cellular Component GO Annotation Evidence References Source
located in cytosol IDA
IDA: Inferred from direct assay
17502455 GOA
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern

CLC Protein Structure

Gal-bind_lectin

Gal-bind_lectin: Galactoside-binding lectin (11 - 136)

  • 0
  • 100
  • 142 a.a.
Protein Preferred Names Protein Names

galectin-10

  • Charcot-Leyden crystal protein

CLC Protein-protein interaction Information

Type
Protein Name Protein ID Interactor Interactor Species Interactor ID Detection Method References
Intra
CLC Q05315 CLC Homo sapiens Q05315
Y2H Array
32296183
Intra
CLC Q05315 CLC Homo sapiens Q05315
Validated Y2H
32296183
Intra
CLC Q05315 CLC Homo sapiens Q05315
Y2H Prey Pooling
32296183
Intra
CLC Q05315 CLC Homo sapiens Q05315
Y2H Array
25416956
Cross: Cross-species interaction Intra: Intraspecies interaction

Recombinant CLC Proteins

Cat. No. Product Name Accession Purity
HY-P700073AF Animal-Free Galectin-10 Protein, Human (His) Q05315 (S2-R142) ≥ 95%, as determined by reducing SDS-PAGE.

Related Diseases

Diseases Alias
Allergic Rhinitis

  • Hay Fever

  • Allergic Rhinitis, Susceptibility To

  • ALRH

  • Atopic Rhinitis

  • Seasonal Allergic Rhinitis

  • Non-Seasonal Allergic Rhinitis

  • Perenial Allergic Rhinitis

  • Pollenosis

  • Rhinitis Allergic Seasonal

  • Rhinitis, Allergic, Perennial

  • Allergic Rhinitis, Cause Unspecified

  • Pollinosis

  • Pollen Allergy

  • Allergy Nos Due To Pollen

  • Summer Catarrh

  • Other Seasonal Allergic Rhinitis
Asthma

  • Chronic Obstructive Asthma

  • Asthma, Diminished Response To Antileukotriene Treatment In

  • Bronchial Hyperreactivity

  • Asthma, Susceptibility To

  • Asthma, Bronchial

  • Asthma, Protection Against

  • Asthma, Nocturnal, Susceptibility To

  • Nocturnal Asthma

  • Asthma-Related Traits

  • Asthma-Related Traits, Susceptibility To

  • Asthma, Nocturnal

  • Chronic Obstructive Asthma With Acute Exacerbation

  • Chronic Obstructive Asthma With Status Asthmaticus

  • Exercise Induced Asthma

  • Exercise-Induced Asthma

  • Bronchial Asthma

  • Asthma, Exercise-Induced

  • Idiosyncratic Asthma

  • Unspecified Asthma With Acute Exacerbation

  • Asthma, Unspecified, With Stated Status Asthmaticus

  • Status Asthmaticus Nos

  • Acute Severe Asthma

  • Acute Severe Bronchial Asthma

  • Status Asthma

  • Status Post Asthmaticus
Galactosemia Iii

  • Galactose Epimerase Deficiency

  • Gale Deficiency

  • Udp-Galactose-4-Epimerase Deficiency

  • Epimerase Deficiency Galactosemia

  • Galactosemia Type 3

  • Gale-D

  • Uridine Diphosphate Galactose-4-Epimerase Deficiency

  • GALAC3

  • Galactosemia 3

  • Generalized Uridine Diphosphate Galactose-4-Epimerase Deficiency

  • Erythrocyte Uridine Diphosphate Galactose-4-Epimerase Deficiency

  • Galactosemia Type Iii

  • Udp-Galactose-4'-Epimerase Deficiency

  • Generalized Galactose Epimerase Deficiency

  • Generalized Gale Deficiency

  • Generalized Gale-D

  • Generalized Udp-Galactose-4-Epimerase Deficiency

  • Generalized Epimerase Deficiency Galactosemia

  • Erythrocyte Galactose Epimerase Deficiency

  • Erythrocyte Gale Deficiency

  • Erythrocyte Gale-D

  • Erythrocyte Udp-Galactose-4-Epimerase Deficiency

  • Erythrocyte Epimerase Deficiency Galactosemia

  • Galactosemias

  • Classical Galactosemia

  • Udpglucose 4-Epimerase Deficiency Disease
Esophagitis, Eosinophilic, 1

  • Eosinophilic Esophagitis

  • EOE1

  • Esophagitis, Eosinophilic

  • Ee
Diseases Alias
Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Waldenstroem'S Macroglobulinemia

Waldenstroem'S Macroglobulinemia

Macroglobulinemia Of Waldenstrom

Lymphoplasmacytic Lymphoma With Igm Gammopathy

Lymphoplasmacytic Lymphoma

Related Agents

  • Approval
  • Clinical Phase
  • Pre-clinical Phase

Approval

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Rare Diseases
HY-106916 Unoprostone Activator 99.0% Unkown

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-122732 OADS Inhibitor 98.25% Phase 4
HY-158183 NMD670 Inhibitor 99.60% Phase 2

Pre-clinical Phase

Bioactive Molecules (13)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-112496 Cl-C6-PEG4-O-CH2COOH 98.0% Unkown
HY-P1105 GaTx2 99.95% Unkown
HY-P2040 Nodularin 99.85% Unkown
HY-186078 SRA-36 Inhibitor 99.79% Unkown
HY-135306 Cl-C6-PEG4-C3-COOH 99.65% Unkown
HY-183088 Cl-C6-PEG8-NH2 hydrochloride / Unkown
HY-43193 Cl-C6-PEG3-C3-acid ≥97.0% Unkown
HY-182571 AK-42 Inhibitor / Unkown
HY-RS02747 CLC Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS02752 CLCF1 Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-W414069 Thiocholesterol / Unkown
HY-RS18058 Clcf1 Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS24533 Clcf1 Rat Pre-designed siRNA Set A Pre-designed Set / Unkown